תבנית:תרופה/צפזולין סנדוז 0.5 גרם - Cefazolin sandoz 0.5 g: הבדלים בין גרסאות
מתוך ויקיתרופות
(יצירת תבנית תרופה) |
מ (יצירת תבנית תרופה) |
||
| שורה 12: | שורה 12: | ||
|התוויה={{{התוויה|<div style="direction:ltr;">Treatment of serious infections caused by susceptible organisms and also perioperatively for prophylaxis. Treatment Respiratory tract: Respiratory tract infections due to streptococcus pneumoniae (formerly diplococcus pneumoniae) klebsiella species haemophilus influenzae staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A B - hemolytic streptococci. Cefazolin is effective in the eradication of streptococci from the nasopharynx. However data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. Urinary tract: Infections due to escherichia coli klebsiella species proteus mirabilis and some strains of Enterobacter and enterococci. Skin and skin structure: -hemolytic beta Infections due to Staphylococcus aureus (penicillin-sensitive and penicillin-resistant) group A streptococci and other strains of streptococci. Biliary tract: Infections due to escherichia coli various strains of streptococci proteus mirabilis klebsiella species and staphylococcus aureus. Bone and joint : Infections due to staphylococcus aureus. Genital infections (i.e. prostatitis epididymitis) due to escherichia coli proteus mirabilis klebsiella species and some strains of enterococci. Septicemia due to streptococcus pneumoniae (formerly diplococcus pneumoniae) staphylococcus aureus (penicillin-sensitive and penicillin-resistant) proteus mirabilis escherichia coli and klebsiella species. Endocarditis caused by staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organism to cefazolin. Perioperative prophylaxis: The prophylactic administraton of cefazolin perioperatively (preoperatively intraoperatively and postoperatively) may reduce the incidence of certain postoperative infectons in patients undergoing surgical procedures (e.g. hysterectomy gastrointestinal surgery and transurethral prostatectomy) that are classified as contaminated or potentially contaminated. The perioperative use of cefazolin may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g. open-heart surgery and prosthetic arthroplasty).</div>}}} | |התוויה={{{התוויה|<div style="direction:ltr;">Treatment of serious infections caused by susceptible organisms and also perioperatively for prophylaxis. Treatment Respiratory tract: Respiratory tract infections due to streptococcus pneumoniae (formerly diplococcus pneumoniae) klebsiella species haemophilus influenzae staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A B - hemolytic streptococci. Cefazolin is effective in the eradication of streptococci from the nasopharynx. However data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. Urinary tract: Infections due to escherichia coli klebsiella species proteus mirabilis and some strains of Enterobacter and enterococci. Skin and skin structure: -hemolytic beta Infections due to Staphylococcus aureus (penicillin-sensitive and penicillin-resistant) group A streptococci and other strains of streptococci. Biliary tract: Infections due to escherichia coli various strains of streptococci proteus mirabilis klebsiella species and staphylococcus aureus. Bone and joint : Infections due to staphylococcus aureus. Genital infections (i.e. prostatitis epididymitis) due to escherichia coli proteus mirabilis klebsiella species and some strains of enterococci. Septicemia due to streptococcus pneumoniae (formerly diplococcus pneumoniae) staphylococcus aureus (penicillin-sensitive and penicillin-resistant) proteus mirabilis escherichia coli and klebsiella species. Endocarditis caused by staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organism to cefazolin. Perioperative prophylaxis: The prophylactic administraton of cefazolin perioperatively (preoperatively intraoperatively and postoperatively) may reduce the incidence of certain postoperative infectons in patients undergoing surgical procedures (e.g. hysterectomy gastrointestinal surgery and transurethral prostatectomy) that are classified as contaminated or potentially contaminated. The perioperative use of cefazolin may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g. open-heart surgery and prosthetic arthroplasty).</div>}}} | ||
|שם יצרן={{{שם יצרן|[[יצרן::SANDOZ GmbH, AUSTRIA]]}}} | |שם יצרן={{{שם יצרן|[[יצרן::SANDOZ GmbH, AUSTRIA]]}}} | ||
| − | |שם בעל הרישום={{{שם בעל הרישום|[[בעל רישום:: | + | |שם יצרן מקוצר=[[שם יצרן מקוצר::SANDOZ| ]] |
| + | |שם בעל הרישום={{{שם בעל הרישום|[[בעל רישום::PERRIGO ISRAEL AGENCIES LTD]]}}} | ||
|רישיון מתאריך={{{רישיון מתאריך|[[רישום מתאריך::10/2009]]}}} | |רישיון מתאריך={{{רישיון מתאריך|[[רישום מתאריך::10/2009]]}}} | ||
| + | |תאריך הגשה={{{תאריך הגשה|[[תאריך הגשה::04/2008]]}}} | ||
|קישור למאגר משרד הבריאות1={{{קישור למאגר משרד הבריאות1|{{מסחרי משרד הבריאות|Cefazolin sandoz 0.5 g|צפזולין סנדוז 0.5 גרם}}}}} | |קישור למאגר משרד הבריאות1={{{קישור למאגר משרד הבריאות1|{{מסחרי משרד הבריאות|Cefazolin sandoz 0.5 g|צפזולין סנדוז 0.5 גרם}}}}} | ||
|עלון לרופא={{{עלון לרופא|[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Cefazolin_Sandoz_Dr_1322643167746.pdf עלון לרופא]}}} | |עלון לרופא={{{עלון לרופא|[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Cefazolin_Sandoz_Dr_1322643167746.pdf עלון לרופא]}}} | ||
| שורה 19: | שורה 21: | ||
|החמרות לעלון={{{החמרות לעלון|}}} | |החמרות לעלון={{{החמרות לעלון|}}} | ||
|מספר רישום={{{מספר רישום|141 69 31812 00}}} | |מספר רישום={{{מספר רישום|141 69 31812 00}}} | ||
| − | |תאריך עדכון=[[עדכון אחרון:: | + | |תאריך עדכון=[[עדכון אחרון::02/02/14]] |
|תמונת אריזה={{{תמונת אריזה|}}} | |תמונת אריזה={{{תמונת אריזה|}}} | ||
|שיווק הופסק={{{שיווק הופסק|לא}}} | |שיווק הופסק={{{שיווק הופסק|לא}}} | ||
| + | |שם ללא מינון={{{שם ללא מינון|צפזולין סנדוז - Cefazolin sandoz}}} | ||
|ללא קטגוריה={{{ללא קטגוריה|<noinclude>-</noinclude>}}} | |ללא קטגוריה={{{ללא קטגוריה|<noinclude>-</noinclude>}}} | ||
}} | }} | ||
<noinclude>{{תרופה/תיעוד}}</noinclude> | <noinclude>{{תרופה/תיעוד}}</noinclude> | ||
גרסה מתאריך 07:13, 2 בפברואר 2014
נתוני תרופה
במרשם 
| קבוצה פרמקולוגית (ATC4) | |
|---|---|
| מרכיב פעיל (ATC5) | Cefazolin AS SODIUM 500 MG/VIAL J01DB04 |
| צורת מתן | I.V; I.M |
| צורת מינון | POWDER FOR SOLUTION FOR INJECTION |
| התוויה | Treatment of serious infections caused by susceptible organisms and also perioperatively for prophylaxis. Treatment Respiratory tract: Respiratory tract infections due to streptococcus pneumoniae (formerly diplococcus pneumoniae) klebsiella species haemophilus influenzae staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A B - hemolytic streptococci. Cefazolin is effective in the eradication of streptococci from the nasopharynx. However data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. Urinary tract: Infections due to escherichia coli klebsiella species proteus mirabilis and some strains of Enterobacter and enterococci. Skin and skin structure: -hemolytic beta Infections due to Staphylococcus aureus (penicillin-sensitive and penicillin-resistant) group A streptococci and other strains of streptococci. Biliary tract: Infections due to escherichia coli various strains of streptococci proteus mirabilis klebsiella species and staphylococcus aureus. Bone and joint : Infections due to staphylococcus aureus. Genital infections (i.e. prostatitis epididymitis) due to escherichia coli proteus mirabilis klebsiella species and some strains of enterococci. Septicemia due to streptococcus pneumoniae (formerly diplococcus pneumoniae) staphylococcus aureus (penicillin-sensitive and penicillin-resistant) proteus mirabilis escherichia coli and klebsiella species. Endocarditis caused by staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organism to cefazolin. Perioperative prophylaxis: The prophylactic administraton of cefazolin perioperatively (preoperatively intraoperatively and postoperatively) may reduce the incidence of certain postoperative infectons in patients undergoing surgical procedures (e.g. hysterectomy gastrointestinal surgery and transurethral prostatectomy) that are classified as contaminated or potentially contaminated. The perioperative use of cefazolin may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g. open-heart surgery and prosthetic arthroplasty).
|
| עלון לרופא והחמרות לעלון |
| ערכים בוויקירפואה | ערכים קשורים בוויקירפואה |
|---|---|
| צפזולין סנדוז 0.5 גרם ® במאגר משרד הבריאות |
| חיפוש מאמרים | - |
|---|---|
| מידע ברשת | - |
| שם יצרן | SANDOZ GmbH, AUSTRIA |
| שם בעל הרישום | PERRIGO ISRAEL AGENCIES LTD |
| רישיון | תאריך הגשה: 04/2008. רישיון מתאריך: 10/2009 |
דף זה נוצר על ידי בוט ומגדיר תבנית עם פרטי התרופה.
- דף התרופה: צפזולין סנדוז 0.5 גרם - Cefazolin sandoz 0.5 g
- לדריסה ידנית של פרטי התרופה: ניתן לערוך את דף התרופה לעיל. לדוגמה החליפו את:
{{תרופה/צפזולין סנדוז 0.5 גרם - Cefazolin sandoz 0.5 g}}
ב:
{{תרופה/צפזולין סנדוז 0.5 גרם - Cefazolin sandoz 0.5 g
| שם הפרמטר=ערך חדש (דורס את הערך שהבוט הגדיר)
}}
